Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.
Compass Pathways tested a new medicine for people whose depression doesn't get better with regular treatments, and it worked well for a whole year. When a company proves its medicine actually helps people, that's a big deal that shows the company might succeed—but results in tests don't always mean the medicine will definitely be approved or sell well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.